Murad A. Jabir, Mahmoud H. Elshoieby, M. Omar, Mohamad Raafat, H. Abou-Taleb, A. H. Hamed
{"title":"Feasibility and efficacy of surgical staging for endometrial cancer by using Pfannenstiel incision","authors":"Murad A. Jabir, Mahmoud H. Elshoieby, M. Omar, Mohamad Raafat, H. Abou-Taleb, A. H. Hamed","doi":"10.15557/cgo.2021.0004","DOIUrl":"https://doi.org/10.15557/cgo.2021.0004","url":null,"abstract":"Objective: The purpose of this study was to evaluate short-term oncological and perioperative outcomes of using Pfannenstiel incision for the surgical staging of endometrial carcinoma. Methods: This was a retrospective cohort study. All patients with endometrial carcinoma referred to the Department of Surgical Oncology, South Egypt Cancer Institute, for surgical staging between January 1, 2014, and July 1, 2016, were enrolled. The patients were grouped according to the type of surgical incision either through Pfannenstiel incision or midline incision, and the groups were compared. Demographic, clinical, operative, and short-term oncological features were analyzed. Results: A total number of 117 patients were recruited, of which 45 patients had Pfannenstiel incision, and 72 patients had midline incision. The clinical and pathological features of patients in both groups were similar. The operative outcomes showed no significant difference between the groups (p > 0.1). Postoperatively, the Pfannenstiel incision group had a statistically significant lower rate of complications compared to the midline incision group (15.5% vs. 38.9%, p = 0.02). The short-term oncological outcomes in the form of total procured lymph nodes or para-aortic lymph nodes were not statistically different (p > 0.1). Conclusion: Pfannenstiel incision can be safely performed for the surgical staging of endometrial cancer with acceptable oncological outcomes compared to the midline incision.","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89323840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Examining the impact of body mass index on overall survival in vulvar, vaginal and other mucosal melanomas: a retrospective cohort study","authors":"S. Naderi-Azad, Faisal Sickandar, R. Pezo","doi":"10.15557/CGO.2020.0009","DOIUrl":"https://doi.org/10.15557/CGO.2020.0009","url":null,"abstract":"Aim of the study: In this retrospective cohort study we have examined differences in survival profiles with respect to the body mass index in patients with mucosal melanoma on immune checkpoint inhibitor therapy. Materials and methods: The primary outcome included the association between the body mass index and overall survival in patients with metastatic mucosal melanoma. The secondary outcomes included the clinical presentation and management of vulvar and vaginal melanomas with oral and anorectal mucosal melanomas, as well as the surgical and radiological management of vulvar and vaginal melanomas. Kaplan–Meier analysis and log-rank test were used for the assessment of overall survival. Results: The results showed that patients with mucosal melanoma whose body mass index was ≥25 had better overall survival (p = 0.02). Overall survival was different between vulvar/vaginal vs. oral mucosal melanoma (p = 0.02). Overall survival was not different between vulvar/vaginal vs. anorectal melanoma (p = 0.77). Some immune toxicities were specific to patients with vulvar/vaginal melanoma. Conclusions: Obesity is associated with improved survival in patients with metastatic mucosal melanoma, although findings can be heterogeneous depending on the subtype of mucosal melanoma.","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86707726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role of long non-coding RNA (lncRNA) in the development of ovarian cancer","authors":"Dorota Gumiela","doi":"10.15557/cgo.2020.0010","DOIUrl":"https://doi.org/10.15557/cgo.2020.0010","url":null,"abstract":"The aim of this study was to review research on the role of long non-coding RNA (lncRNA) in ovarian cancer. This article analyses studies on the effect of increased lncRNA expression on the size of ovarian cancer and the incidence of metastasis. The review covers a period from October 15, 2018 to August 22, 2020, and comprises 23 studies in which a total of 1,580 women with ovarian cancer participated, and an undetermined number of control groups where healthy tissue samples were collected. A review of the studies indicates that increased lncRNA expression is associated with elevated ovarian cancer size and metastatic risk. The most studied lncRNA include HOTAIR, CCAT2, GAS5, MALAT-1, UCA1. Studies assessing the expression levels of HOTAIR lncRNA and CCAT2 in normal and cancer tissue showed varying levels of expression in studies of different authors, which indicates that the expression of the same lncRNA may vary individually or is a result of study errors.","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85560462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maryam Nakhaie Moghadam, Sonia Nourkhomami, L. Seresht, H. Azimi, S. Bolandi, T. Zavari, Z. Yousefi
{"title":"B-hCG and H-hCG levels in patients with gestational trophoblastic neoplasia","authors":"Maryam Nakhaie Moghadam, Sonia Nourkhomami, L. Seresht, H. Azimi, S. Bolandi, T. Zavari, Z. Yousefi","doi":"10.15557/CGO.2020.0007","DOIUrl":"https://doi.org/10.15557/CGO.2020.0007","url":null,"abstract":"Objective: Gestational trophoblastic disease is a term that encompasses a spectrum of disorders all arising from the placenta. Human chorionic gonadotropin (hCG) hormone has an essential role in the diagnosis and management of gestational trophoblastic neoplasia. Measuring beta-hCG (B-hCG) levels is the only standard method of monitoring treatment response in patients on chemotherapy. Serial B-hCG levels are also helpful in defining the suitable approach and the dosage of chemotherapeutic drugs. Unfortunately, this marker may not be helpful in some cases. Therefore, the present study was conducted to determine the results of the ratio of B-hCG and hyperglycosylated human chorionic gonadotropin (H-hCG) in patients with gestational trophoblastic neoplasia. Materials and methods: This was a cross-sectional study in 22 patients with gestational trophoblastic neoplasia who were referred to an oncology clinic of an academic hospital of Mashhad University of Medical Sciences in Iran from December 2017 to May 2018. Inclusion criteria were plateau level of B-hCG (during 4 weeks) or persistent low level of hCG. After ruling out other etiologies, H-hCG level was measured and the H-hCG/total hCG ratio was evaluated. If the proportion was more than 20%, active gestational trophoblastic neoplasia was diagnosed, and if it was less than 20%, quiescent gestational trophoblastic neoplasia was diagnosed. In patients with active gestational trophoblastic neoplasia, interventional procedures involved a change in the dose intensity or chemotherapy or proposing a surgery. However, only serial follow-up was recommended in patients with quiescent gestational trophoblastic neoplasia. Then, the patients were followed during the therapy and the condition of patients was followed and recorded. Results: The mean age of patients was 31.36 ± 8.01 years. Hydatidiform mole was the most common diagnosis, accounting for approximately 64% (14) of patients. A total of 81% of patients were undergoing chemotherapy. The interval time between the onset of chemotherapy until plateau or persistent low level of hCG was 11.26 ± 4.03 weeks. The mean B-hCG level was 36.6 mIU/mL and the mean H-hCG/total hCG ratio was 6.24%. This proportion was less than 20% in 82% of patients. Among these patients, 14 patients (77.8%) had spontaneously normalized levels of B-hCG during a 6-month follow-up. Two cases underwent chemotherapy due to increased B-hCG. Other patients are still under follow-up without disease progression. Among 4 patients with a H-hCG/total hCG ratio >20%, hysterectomy was recommended to one patient duo to multiparity and the fact that the tumor was localized in the uterus. In the other patients, an increase in the dose of methotrexate or a change of chemotherapy regimen was performed, which caused a decrease in B-hCG level to normal. All patients are still under follow-up without disease progression. Conclusion: The data in this study suggests the use of H-hCG as a tumor marker in pat","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80180966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Foam cell formation associated with a borderline ovarian tumor: a case report","authors":"Jung-Woo Park","doi":"10.15557/CGO.2020.0011","DOIUrl":"https://doi.org/10.15557/CGO.2020.0011","url":null,"abstract":"Foam cell formation is a very common pathologic finding in atherosclerosis, often found in some major organs. However, the involvement of the retroperitoneal organs is very rare and foam cell formation associated with borderline ovarian tumor has not been reported. Borderline ovarian tumors are epithelial ovarian tumors with a low growth rate, low potential to invade or metastasize, and excellent prognosis. Still, a rapidly growing borderline ovarian tumor can exert pressure on the retroperitoneal organs. It may cause retroperitoneal irritation and inflammation, and form a mass lesion in adjacent organs. We report the case of a 41-year-old woman with a borderline ovarian tumor and foam cell infiltration.","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78904727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immunotherapy toxicities in metastatic vulvar and vaginal melanomas: a retrospective cohort study","authors":"S. Naderi-Azad, Faisal Sickander, R. Pezo","doi":"10.15557/cgo.2020.0008","DOIUrl":"https://doi.org/10.15557/cgo.2020.0008","url":null,"abstract":"This retrospective cohort study examined the factors for patients with metastatic vulvar and vaginal melanomas on immune checkpoint inhibitors. The study included all patients over the age of 18 who received either anti-cytotoxic T-lymphocyte-4 (anti-CTLA-4) therapy or anti-programmed cell death protein-1 (anti-PD-1) therapy at the Sunnybrook Hospital from June 2012 to December 2018. There were 11 patients with vulvar or vaginal melanoma on immune checkpoint inhibitor therapy. The main sites of metastasis included the lungs, lymph nodes, soft tissues, and liver. The majority of patients received prior radiation therapy (7/11) and prior surgical therapy (9/11). There were no differences in overall survival for vulvar or vaginal melanomas on anti-PD-1 vs. anti-CTLA-4 therapy (p > 0.05). There were no significant differences in overall survival for vulvar and vaginal vs. cutaneous melanoma (p > 0.5). There were no significant differences in overall survival in patients with vulvar and vaginal melanoma in the presence vs. absence of immune-related adverse events (p > 0.05), yet there was a significant difference in patients with cutaneous melanoma in the presence vs. absence of immune-related adverse events (p < 0.05). Knowledge of the presentation and outcome of vulvar and vaginal melanomas is important for clinical practice in gynecology.","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"114 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89392460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cesarean scar pregnancy management: medical or surgical? When and which? A literature review","authors":"G. Demirtas","doi":"10.15557/cgo.2020.0002","DOIUrl":"https://doi.org/10.15557/cgo.2020.0002","url":null,"abstract":"","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"441 1","pages":"7-11"},"PeriodicalIF":0.0,"publicationDate":"2020-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82912498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A rare case of perineal endometriosis in an episiotomy scar","authors":"E. Al-Ojaimi, Janan Alajaimi","doi":"10.15557/cgo.2020.0006","DOIUrl":"https://doi.org/10.15557/cgo.2020.0006","url":null,"abstract":"","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"16 1","pages":"28-33"},"PeriodicalIF":0.0,"publicationDate":"2020-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89805149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Puntambekar, Kshitij Manerikar, M. Chitale, A. Goel, Deep M. Bhadra, R. Sathe, Mangesh Panse
{"title":"Laparoscopic nerve-sparing radical trachelectomy: retrospective study of four patients","authors":"S. Puntambekar, Kshitij Manerikar, M. Chitale, A. Goel, Deep M. Bhadra, R. Sathe, Mangesh Panse","doi":"10.15557/cgo.2020.0005","DOIUrl":"https://doi.org/10.15557/cgo.2020.0005","url":null,"abstract":"","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"23 1","pages":"21-27"},"PeriodicalIF":0.0,"publicationDate":"2020-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82511567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Uterine sarcomas: 7-year experience from a tertiary center","authors":"M. H. Yetimalar, D. Kiliç, S. Yiğit","doi":"10.15557/cgo.2020.0001","DOIUrl":"https://doi.org/10.15557/cgo.2020.0001","url":null,"abstract":"","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"31 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2020-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77785044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}